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ABSTRACT
Objective: Following an acute stroke, there is a high
risk of recurrence. However, the leading cause of
mortality following a stroke is due to coronary artery
disease (CAD) and myocardial infarction (MI) but that
risk has not been robustly quantified. We sought to
reliably quantify the risk of ischaemic heart disease
(IHD) in patients presenting with acute ischaemic
stroke (AIS) in the absence of a known cardiac history.
Setting: A meta-analysis study. PubMed, MEDLINE,
EMBASE and Google Scholar were searched for
potential studies up to October 2015. Included studies
reported an acute cerebral ischaemic event and
followed for CAD or MI within 1 year in patients
without known IHD. Using arcsine transformed
proportions for meta-analysis, studies were combined
using a generic inverse variance random-effects model
to calculate the pooled standardised mean difference
and 95% CIs. These were interpreted as the percentage
prevalence of CAD or incidence of MI following AIS.
Results: 17 studies with 4869 patients with AIS
demonstrated a mean average of asymptomatic CAD in
52%. Anatomical methods of CAD detection revealed a
prevalence of asymptomatic ≥50% coronary stenosis
in 32% (95% CI 19% to 47%; p<0.00001). 8 studies
with 47229 patients with ischaemic stroke revealed an
overall risk of MI in the year following stroke of 3%
(95% CI 1% to 5%; p<0.00001) despite the absence of
any cardiac history.
Conclusions: One-third of patients with ischaemic
stroke with no cardiac history have more than 50%
coronary stenosis and 3% are at risk of developing MI
within a year. Our findings provide a reliable
quantitative measure of the risk of IHD following AIS in
patients with no cardiac history.
INTRODUCTION
Cardiovascular disease is the single leading
cause of mortality worldwide,1 costing the
UK economy £19 billion every year, with the
National Health Service in England spend-
ing around £6.8 billion on cardiovascular
disease in 2012/2013.2 Given our ageing
population and global increase in non-
communicable diseases, the burden of heart
disease and stroke is becoming an ever
increasing public health issue.3
Atherosclerosis as a systemic process;
common risk factors and pathophysiology
exists between ischaemic stroke, coronary
artery disease (CAD) and myocardial infarc-
tion (MI).4 Any acute atherosclerotic event
increases the risk for another in the same or
different vascular bed.5 Following an acute
ischaemic stroke (AIS), there is a high short-
term risk of recurrence; however, the leading
cause of mortality in these patients is MI.4 6 7
A number of studies have evaluated the
relationship between stroke and MI yet show
varying results on the rate of subsequent car-
diovascular events6 8 9 with wide discrepancy
in the observed prevalence of asymptomatic
CAD ranging from 15% to 80% following
AIS.10 11 While it is probable that those with
an established history of ischaemic heart
disease (IHD) will account for the majority
of subsequent coronary events following AIS,
the true risk of CAD and MI in patients with
stroke in the absence of a cardiac history is
unclear.
Strengths and limitations of this study
We study the risk of heart disease following a
stroke in those patients with no cardiac history.
This study is the largest of its kind and, by bringing
together multiple data sets, robustly quantifies the
risk of heart disease following stroke. As with all
meta-analyses, the main limitation of this work
relates to publication bias.
▪ Most patients with stroke die of heart disease.
▪ One in three patients with ischaemic stroke with
no cardiac history have more than 50% coronary
stenosis.
▪ 3% are at risk of developing myocardial infarc-
tion within a year of their stroke.
▪ Patients with stroke need to be screened for
silent heart disease and appropriate and aggres-
sive management of total cardiovascular risk
factors is required.
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In an attempt to provide clarity and quantiﬁcation on
this issue, we conducted a systematic review and
meta-analysis to determine the prevalence of asymptomatic
CAD and incidence of MI in patients with AIS in the
absence of previous cardiac disease. To the best of our
knowledge, this is the largest such study conducted to date.
METHODS
Data sources
A search was performed using electronic databases
PubMed, MEDLINE, EMBASE and Google Scholar to
identify all relevant published studies up to October
2015. The search strategy included keywords with syno-
nyms and MeSH terms:[stroke] OR[cerebrovascular acci-
dent] OR[CVA brain] OR[cerebral infarction] OR
[transient ischaemic attack] OR[transient ischemic
attack] OR[TIA] OR[Cerebral Infarction] OR[Stroke]
OR[Brain Ischemia] OR[Ischemic Attack] OR
[Transient], along with[asymptomatic coronary artery
disease] OR[asymptomatic CAD];[asymptomatic coron-
ary heart disease] OR[asymptomatic CHD], along with
[subclinical ischaemic heart disease] OR[silent myocar-
dial infarction] OR[silent MI] OR[silent myocardial
ischaemia]. Search criteria were limited to humans. All
terms were then subjected to interaction with each other
with Boolean operators AND or OR. Foreign language lit-
erature was included and papers translated where neces-
sary. Manual searches identiﬁed additional studies from
the references of electronically identiﬁed studies.
Study selection
Studies were selected by TG, NH and JS if they fulﬁlled
the following inclusion criteria: (1) acute onset of stroke
or transient ischaemic attack (TIA); (2) lesion con-
ﬁrmed by brain imaging (CT/MRI) or at autopsy; (3)
investigations for CAD with acceptable levels of sensitiv-
ity and speciﬁcity12; (4) diagnosis of MI according to cri-
teria of the third universal deﬁnition proposed by
international expert consensus,13 and (5) follow-up data
for CAD or MI up to 1 year from stroke onset.
Studies were excluded if: (1) age<18 years; (2) haem-
orrhagic stroke and (3) history of IHD (CAD or MI),
unless subgroup data were presented for extraction.
Owing to the low speciﬁcity of ECG to detect ischaemia,
investigations using ECG or exercise ECG alone were
excluded, except when in conjunction with another
modality of testing such as troponin.14 Where duplicate
studies were identiﬁed, data from the latest data set were
used. In an attempt to enhance the quality of our ana-
lyses, only studies that recruited a minimum of 50 parti-
cipants were included for ﬁnal analysis. Studies with a
higher minimum number of participants were more
likely to be conducted in a systematic manner with a
probably more reliable result.15 We used the STROBE16
checklist as an initial screen of cohort studies and to
extract data, MOOSE17 criteria for the reporting of
observational studies and the PRISMA statement to
guide our reporting of the meta-analyses.18
Data extraction
Data extraction was undertaken independently by two
investigators (TG and JS) and any disagreements were
resolved by consensus or by the opinion of a third reviewer.
For each selected study, the total population of patients
with ischaemic stroke without a history of IHD and the pro-
portion with asymptomatic CAD or MI were extracted.
Additional information on study design, method of CAD/
MI diagnosis, as well as baseline characteristics such as
mean age, sex, ethnicity and the presence of risk factors
for cardiovascular disease, was documented.
Statistical analysis
Since this was a one-sided investigation without a com-
parison group, a double arcsine transformation was used
for proportion meta-analysis.19 20 For each study, the
proportion of patients with stroke who were positive for
asymptomatic CAD or silent MI from the total popula-
tion of patients was recorded. The proportions P within
the populations were calculated by dividing the number
of positive events by the number of patients with stroke
without known heart disease.
The standardised mean difference (SMD) and SE for
each proportion were then calculated: Standardised
mean difference (SMD)=2×arcsin (√P) and SE was gen-
erated by 1/√n. The results were combined using a
generic inverse variance random-effects model
(DerSimonian and Laird) to calculate weighted pooled
SMD and 95% CIs using review manager SMD=(A).21
The concluding result was interpreted as the percentage
prevalence of CAD or incidence of MI by transforming
data back to the original scale to give pooled percentage
prevalence: % prevalence=(sin×(A/2)2)×100.22
To accurately determine the prevalence of asymptom-
atic CAD, meta-analysis was restricted to studies report-
ing more sensitive methods of CAD investigation and
signiﬁcant coronary artery occlusion (≥50% stenosis).
Tests for heterogeneity and sensitivity analysis were per-
formed by systematically and iteratively removing one
study at a time and re-running the model to determine
the overall effect size. On the basis of the statistical
method used, it was not possible or appropriate to assess
for publication bias in this study.20
RESULTS
In total, 1308 records were identiﬁed and, following
screening for exclusions, a total of 24 studies met our
inclusion criteria (ﬁgure 1). Seventeen studies with 4869
patients with AIS/TIA investigated for asymptomatic
CAD and eight studies with 47 229 patients demon-
strated risk of MI following ischaemic stroke in those
without a cardiac history (table 1). Twenty-three studies
recruited patients prospectively.
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Prevalence of asymptomatic CAD
There was a similar proportion of males to females in
each of the included studies, with an average of 55%
males and a mean age of 66 years. With the exception
of a single autopsy study23 where the median time
between stroke and death was 12 days (IQR 5–32 days),
all studies recruited patients with stroke within 10 days.
While most studies included ischaemic stroke of athero-
sclerotic aetiology, three studies excluded cardioem-
bolic stroke5 10 32 and only one study included those
with suspected cardioembolism.29 Three studies looked
exclusively at ﬁrst ischaemic stroke.28 32 27 There were
limited data available for the risk factors present in
patients found to have asymptomatic CAD; where evalu-
ated, there were varying levels of all risk factors, except
hypertension which coexisted in 42–67% of patients
with stroke and was as high as 96% in one study.24
Owing to the variety of methods of investigation with
varying levels of sensitivity, and wide range of results, it
was not appropriate to perform a meta-analysis on all
17 studies, but the mean average of asymptomatic CAD
was 52%.
Meta-analysis was performed on 11 studies using cor-
onary angiography, CT coronary angiography (CTCA),
coronary calcium score (CCS) and autopsy as more sen-
sitive investigations for asymptomatic CAD in patients
with AIS. This revealed for any degree of coronary
plaque a pooled SMD of 1.41 (95% 1.16 to 1.66;
T2=0.27; I2=99%; p<0.00001) equivalent to a prevalence
of 53% (95% CI 43% to 63%) (ﬁgure 2). A pooled
SMD of 1.20 (95% CI 0.89 to 1.51; T2=0.27; I2=99%;
p<0.00001) was observed (ﬁgure 3), equivalent to a
prevalence of ≥50% asymptomatic coronary stenosis of
32% (95% CI 19% to 47%). Signiﬁcant heterogeneity
was observed, which was unchanged following iterative
analysis, removal of patients with TIA5 31 and a unique
autopsy study conducted prior to the year 2000.23
Prevalence of any degree of coronary artery stenosis was
not statistically signiﬁcant, most likely due to the high
variance in the studies analysed. However, removal of
non-Caucasian populations11 25–31 yielded a statistically
signiﬁcant pooled SMD of 1.03 (95% CI 0.88 to 1.17;
p=0.01), equivalent to an asymptomatic CAD prevalence
of 24% (95% CI 18% to 30%).
Incidence of myocardial infarction
With the exception of one study,39 all eight studies pro-
spectively recruited patients with stroke. The majority of
studies were based in predominately Caucasian popula-
tions from across Europe, Canada and the USA. The
largest observational study included a total of 37 214 par-
ticipants from multiple stroke centres across Austria.37
For each study, there were similar demographics includ-
ing a balanced proportion of males to females, with an
average of 53% males and a mean age of 70 years. There
were limited data evaluating risk factors in those patients
with MI which was diagnosed within 3 months of the AIS
and, in most studies in-hospital. A pooled SMD of 0.35
(95% CI 0.24 to 0.46; T2=0.02; I2=98%; p<0.00001)
equivalent to a total MI incidence of 3% (95% CI 1% to
5%) in patients with stroke with no cardiac history
(ﬁgure 4).
DISCUSSION
This study, which quantities the risk of IHD following
ischaemic stroke, revealed that over half of such patients
with stroke have evidence of asymptomatic coronary
Figure 1 Flow diagram of
search strategy (CAD, coronary
artery disease; MI, myocardial
infarction).
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Table 1 Studies and their characteristics
Asymptomatic CAD MI
Study Location
Male
(%)
Mean
age Ischaemic event Method of investigation N n
Per
cent
>50%
stenosis n
Per
cent
Gongora-Rivera
et al,23 MASS
France 55 60 Fatal stroke Autopsy: plaque, ischaemia,
MI necrosis/fibrosis >1 cm
188 131 70 29 59 31
Amarenco et al,24
AMISTAD
France 72 62 Stroke Coronary angiography 315 195 62 26 – –
Ahn et al25 Korea 65 66 Stroke/TIA CTCA 314 145 46 46
Calvet et al,5
PRECORIS
France 70 63 Stroke/TIA CTCA 274 133 49 18 – –
Cha et al26 Korea 64 63 Stroke/TIA CTCA 1733 1220 70 33
Cho et al27 Korea 60 68 1st stroke CTCA 274 158 58 22 – –
Hoshino et al28 Japan 72 66 1st stroke CTCA 100 36 36 36 – –
Iwasaki et al11 Japan 67 63 Stroke CCS (calcium score) 151 37 25 25 – –
Kim et al29 Korea 70 67 Stroke CTCA 200 161 81 36 – –
Seo et al30 Korea 63 68 Stroke CTCA 71 18 25 25 – –
Yoon et al31 Korea 50 71 Stroke/TIA CTCA 175 105 60 21 – –
Arauz et al32 Mexico 69 62 1st stroke Stress SPECT 125 40 32 – – –
Chimowitz et al33 USA 64 61 Stroke/TIA Stress thallium myocardial
scintigraphy
65 23 35 – – –
Di Pasquale et al34 Italy 73 56 Stroke/TIA of the
carotid system
Exercise thallium myocardial
imaging
140 33 24 – – –
Urbinati et al35 Italy 71 64 Stroke/TIA of the
carotid system
Exercise thallium myocardial
scintigraphy
121 28 23 – – –
Nighoghossian et al10 France 80 59 Stroke Stress echo 60 9 15 – – –
Leys et al,36 DETECT France 74 69 Stroke ECG+echo 563 64 11 – – –
Gattringer et al37 Austria 53 74 Stroke/TIA Troponin+ECG 37 214 – – – 181 0.5
Jensen et al38 Denmark 52 75 Stroke Troponin+ECG 244 – – – 7 3
Lee et al39 Korea 56 67 Stroke Troponin+ECG 1247 – – – 8 1
Liao et al40 Canada 52 72 Stroke Troponin+ECG 7199 – – – 129 2
Mathias et al41 USA 52 64 Stroke Troponin+ECG+echo 323 – – – 7 2
Prosser et al,42 VISTA Canada, Germany,
Sweden, UK, USA
49 73 Stroke Cardiac mortality & serious
cardiac adverse events
458 – – – 33 7
Song et al43 Korea 56 72 Stroke Troponin+ECG 356 – – – 0 0
AMISTAD, Asymptomatic Myocardial Ischemia in Stroke and Atherosclerotic Disease; CAD, coronary artery disease; CCS, coronary calcium score; CTCA, CT coronary angiography; MASS,
Multiple Atherosclerosis Site in Stroke; MI, myocardial infarction; TIA, transient ischaemic attack.
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plaque and one in three patients have an occlusion of
clinical signiﬁcance (>50% stenosis). Given the strong evi-
dence linking coronary artery stenosis >50% to the high
risk of acute MI,44 45 and our ﬁndings that 3% of patients
with ischaemic stroke suffer from MI within 1 year, it is
clear that many more individuals with no history of IHD
may be at risk of MI than previously appreciated.
Our results are supported by previously published data
that demonstrate a high burden of coronary plaque
even when there is no previous evidence of systemic
disease. The Asymptomatic Myocardial Ischemia in
Stroke and Atherosclerotic Disease (AMISTAD) study set
out to determine whether asymptomatic coronary ath-
erosclerosis predicts a higher risk of major vascular
event in patients with stroke and found that, from a
baseline diagnosis of asymptomatic CAD, the 2-year HR
of patients with stroke developing ≥1 vessel disease (cor-
onary stenosis >50%) was 3.43 (95% CI 1.48 to 7.93).24
In the Multiple Atherosclerosis Site in Stroke (MASS)
study, patients with stroke with no atherosclerotic plaque
in the cerebral arteries demonstrated prevalence of cor-
onary plaque as high as 51%.23 Thus, despite the limita-
tions in predicting the presence of asymptomatic CAD,
based on the detection of extra-cardiac atherosclerosis,
an association exists and there is a signiﬁcant global vas-
cular burden in patients with stroke.
There are limited data to compare our results with the
prevalence of subclinical atherosclerosis in an asymp-
tomatic population of similar age. A Norwegian study in
1852 asymptomatic male ofﬁce workers found that 2.7%
had at least one coronary stenosed artery ≥50% by cor-
onary angiography.46 A recent European study with 244
asymptomatic patients undergoing CTCA found a 5%
prevalence of obstructive CAD requiring further investi-
gation.47 One larger Korean study with 6311 asymptom-
atic patients found a prevalence of coronary
atherosclerosis >50% stenosis in 9% by CTCA.48 Thus,
there is considerable difference in cardiac risk between
Figure 2 Forest plot: prevalence of asymptomatic coronary artery disease after stroke.
Figure 3 Forest plot: prevalence of asymptomatic coronary artery disease >50% stenosis after stroke.
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the asymptomatic population and patients with stroke,
with a prevalence gap from these few studies ranging
between 23% and 29%.
Following a cerebrovascular ischaemic event, patients
with no known IHD history the Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL)
trial demonstrated not only the high risk of cardiac
events but also supports the beneﬁts of statin therapy in
the treatment of stroke when considering this ischaemic
event as a coronary risk equivalent.49 In determining the
beneﬁcial effects of blood pressure reduction, the
Perindopril Protection Against Recurrent Stroke Study
(PROGRESS) found that 1.2% of patients with ischae-
mic stroke went on to have non-fatal MI or death
accountable to coronary heart disease (CHD), conclud-
ing that secondary prevention should target the cause of
the original event as well as mixed vascular risk factors.50
The results from an older meta-analysis6 calculated a
2.2% annual risk of MI after ischaemic stroke/TIA,
although it failed to estimate the risk of MI according to
the cardiac history. Our results support proposals of the
American Heart Association and American Stroke
Association recommending that patients with stroke be
considered for further cardiac evaluation on the basis of
their individual cardiovascular risk factor proﬁle.50 51
Despite our efforts, no meta-analysis is free from publi-
cation bias. A considerable level of heterogeneity in our
analyses reﬂects clinical differences between the studies
with inclusion of different subtypes of ischaemic events
partly accounting for some of the observed variation. In
particular, the different investigations to determine the
extent and severity of coronary stenosis (eg, formal cor-
onary angiography, CT angiogram, CCS) may not be
equally comparable in terms of their assessment of sten-
osis. Although we categorise the data by cardiac investi-
gation in table 1, the overall pooled result is subject to
this limitation. To limit the effect of major differences
occurring in clinical cardiovascular care, studies prior to
the year 2000 were removed. We attempted to improve
quality control by incorporating studies with at least 50
participants. These larger studies tend to be better con-
ducted. Study populations located worldwide demon-
strated the global burden of asymptomatic disease;
however, our results should be extrapolated to other
ancestral populations with caution.
We demonstrate that up to a third of patients with
ischaemic stroke with no cardiac history have more than
50% coronary stenosis and 3% are at risk of developing
MI within 1 year following their stroke even in the
absence of any previous cardiac symptoms. The cardiac
risk posed to patients with ischaemic stroke is substantial
even in the absence of an IHD history.
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